August 9, 2006 -- Millennium Pharma received Priority Review designation of an add-on indication for Velcade; MGI Pharma sold the US rights for Aggrastat Injection for $19 million plus royalties; Santarus rose after releasing Q2 financials; Edwards sold the remaining piece of its perfusion products business; Threshold completed enrollment in two clinical trials of glufosfamide for pancreatic cancer; and Genaera will ask shareholders to approve a reverse split of its stock. The Centient Biotech 200™ ended the day with a 10-point loss at 3603.52, a drop of .29%. More details...
